Cytek Biosciences (CTKB) News Today

Vanguard Group Inc. increased its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 7.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,890,700 shares of the company'

Wellington Management Group LLP lessened its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,291,258 shares of the company's stock aft

Cytek Biosciences (NASDAQ:CTKB) Shares Up 3.6%

Cytek Biosciences (NASDAQ:CTKB) Trading Down 7.5%

Brown Capital Management LLC lessened its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 11.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,016,325 shares of the company's stock after selling 1,544,155 shares

Cytek Biosciences (NASDAQ:CTKB) Trading Up 4.2%

Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $6.00

Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down to $5.96

Piper Sandler decreased their price target on shares of Cytek Biosciences from $10.00 to $8.50 and set an "overweight" rating on the stock in a report on Monday.

Cytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591278)

Cytek Biosciences (NASDAQ:CTKB) Trading Up 6.6%

New York State Common Retirement Fund raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,947,986 shares of

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of the stock in a transaction on Friday, April 19th. The stock was sold at an average price of $5.87, for a total value of $117,400.00. Following the sale, the chief technology officer now directly owns 5,988,502 shares in the company, valued at $35,152,506.74. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 9,950,000 shares, a growth of 16.9% from the March 15th total of 8,510,000 shares. Approximately 8.4% of the company's shares are short sold. Based on an average daily trading volume, of 723,300 shares, the short-interest ratio is presently 13.8 days.

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 1,900 shares of the stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $7.00, for a total transaction of $13,300.00. Following the completion of the sale, the chief technology officer now owns 6,008,502 shares of the company's stock, valued at approximately $42,059,514. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Vanguard Group Inc. increased its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 4.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,079,421 shares of the company's stock a

Cytek Biosciences (NASDAQ:CTKB) Shares Up 5%

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 8,510,000 shares, an increase of 9.2% from the February 29th total of 7,790,000 shares. Currently, 7.1% of the company's shares are short sold. Based on an average trading volume of 731,300 shares, the days-to-cover ratio is currently 11.6 days.

Cytek Biosciences (NASDAQ:CTKB) Shares Down 3.3%

Cytek Biosciences (NASDAQ:CTKB) Shares Down 4.8% Following Insider Selling

Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $6.77, for a total value of $135,400.00. Following the completion of the transaction, the chief technology officer now directly owns 6,030,402 shares in the company, valued at $40,825,821.54. The sale was disclosed in a filing with the SEC, which is available through this link.

RA Capital Management L.P. decreased its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 44.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,809,404 shares of the company's stock afte

Piper Sandler lowered their price objective on shares of Cytek Biosciences from $11.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday.